162 related articles for article (PubMed ID: 21751242)
1. Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: a novel mechanism mediating its blockade of osteoclastogenesis.
Cheng J; Liu J; Shi Z; Xu D; Luo S; Siegal GP; Feng X; Wei S
J Cell Biochem; 2011 Nov; 112(11):3385-92. PubMed ID: 21751242
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling.
Kalliolias GD; Zhao B; Triantafyllopoulou A; Park-Min KH; Ivashkiv LB
Arthritis Rheum; 2010 Feb; 62(2):402-13. PubMed ID: 20112358
[TBL] [Abstract][Full Text] [Related]
3. IL-1R/TLR2 through MyD88 Divergently Modulates Osteoclastogenesis through Regulation of Nuclear Factor of Activated T Cells c1 (NFATc1) and B Lymphocyte-induced Maturation Protein-1 (Blimp1).
Chen Z; Su L; Xu Q; Katz J; Michalek SM; Fan M; Feng X; Zhang P
J Biol Chem; 2015 Dec; 290(50):30163-74. PubMed ID: 26483549
[TBL] [Abstract][Full Text] [Related]
4. Defective entry into mitosis 1 (Dim1) negatively regulates osteoclastogenesis by inhibiting the expression of nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1).
An D; Kim K; Lu W
J Biol Chem; 2014 Aug; 289(35):24366-73. PubMed ID: 25023277
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling.
Wei S; Wang MW; Teitelbaum SL; Ross FP
J Biol Chem; 2002 Feb; 277(8):6622-30. PubMed ID: 11719504
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.
Jules J; Zhang P; Ashley JW; Wei S; Shi Z; Liu J; Michalek SM; Feng X
J Biol Chem; 2012 May; 287(19):15728-38. PubMed ID: 22416138
[TBL] [Abstract][Full Text] [Related]
7. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
8. IL-33 inhibits RANKL-induced osteoclast formation through the regulation of Blimp-1 and IRF-8 expression.
Kiyomiya H; Ariyoshi W; Okinaga T; Kaneuji T; Mitsugi S; Sakurai T; Habu M; Yoshioka I; Tominaga K; Nishihara T
Biochem Biophys Res Commun; 2015 May; 460(2):320-6. PubMed ID: 25795135
[TBL] [Abstract][Full Text] [Related]
9. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
[TBL] [Abstract][Full Text] [Related]
11. Complex regulation of tartrate-resistant acid phosphatase (TRAP) expression by interleukin 4 (IL-4): IL-4 indirectly suppresses receptor activator of NF-kappaB ligand (RANKL)-mediated TRAP expression but modestly induces its expression directly.
Yu M; Moreno JL; Stains JP; Keegan AD
J Biol Chem; 2009 Nov; 284(47):32968-79. PubMed ID: 19801646
[TBL] [Abstract][Full Text] [Related]
12. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
[TBL] [Abstract][Full Text] [Related]
13. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
14. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
[TBL] [Abstract][Full Text] [Related]
15. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1.
Tran PT; Dat NT; Dang NH; Van Cuong P; Lee S; Hwangbo C; Van Minh C; Lee JH
Phytomedicine; 2019 Mar; 55():1-8. PubMed ID: 30668419
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
17. IL-4 inhibits TNF-α-mediated osteoclast formation by inhibition of RANKL expression in TNF-α-activated stromal cells and direct inhibition of TNF-α-activated osteoclast precursors via a T-cell-independent mechanism in vivo.
Fujii T; Kitaura H; Kimura K; Hakami ZW; Takano-Yamamoto T
Bone; 2012 Oct; 51(4):771-80. PubMed ID: 22776139
[TBL] [Abstract][Full Text] [Related]
18. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
